期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 86, 期 2, 页码 339-344出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2021.10.004
关键词
basal cell carcinoma; JAK1; JAK2; myelofibrosis; nonmelanoma skin cancer; polycythemia vera; ruxolitinib; squamous cell carcinoma
类别
资金
- NCI Cancer Center Support grant [P30 CA124435]
- Stanford NIH/NCRR CTSA award [UL1 TR003142]
- Stanford Medical Scholars Program
This study systematically assessed the risk of developing nonmelanoma skin cancers (NMSCs) after ruxolitinib exposure in patients with polycythemia vera (PV) or myelofibrosis (MF). The results showed that ruxolitinib exposure is associated with an increased risk of squamous cell carcinoma (SCC) in PV or MF patients, particularly in non Janus kinase 2-mutated patients.
Background: Clinical trials report occurrence of nonmelanoma skin cancers (NMSCs) with ruxolitinib in patients with polycythemia vera (PV) or myelofibrosis (MF); however, the level of risk and effect of covariates are not known in the real-world setting. Objective: To systematically assess the risk of developing NMSC after ruxolitinib exposure in patients with PV or MF. Methods: A 10-year retrospective cohort of patients with PV or MF at Stanford Medical Center was identified and matched according to age, gender, race, Charlson Comorbidity Index, disease diagnosis, and follow-up time. The main outcome measure was hazard ratio (HR) for NMSC (comprised of basal cell carcinoma and squamous cell carcinoma [SCC]) after ruxolitinib exposure, adjusted for covariates. Results: The study cohort consisted of 564 patients (188 exposed to ruxolitinib for at least 4 weeks, 376 unexposed). Ruxolitinib-exposed patients with PV or MF had an adjusted NMSC HR of 2.69 (95% CI, 1.037.02). In particular, ruxolitinib exposure was associated with SCC (HR, 3.24; 95% CI, 1.45-7.22), with non Janus kinase 2-mutated patients showing even higher SCC risk (HR, 7.40; 95% CI, 2.54-21.63). Limitations: Retrospective design. Conclusions: Our real-world results indicate that SCC risk is increased in patients with PV or MF taking ruxolitinib and support consideration of skin cancer monitoring.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据